Physician profile
Albert A Rizzo
NPI 1245283316
$161,804.31
in general payments reported to CMS, 2019-2025
17 companies · $11K in 2025
The $11K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $39K · 2021: $25K · 2022: $7,188 · 2023: $9,043 · 2024: $2,674 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $10K · Food and Beverage: $1,177 · Travel and Lodging: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,575.00 |
| Consulting Fee | $10,380.00 |
| Food and Beverage | $1,177.28 |
| Travel and Lodging | $169.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $50,406.65 | 2019-2021 | |
| Genzyme Corporation | $27,813.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21,407.59 | 2019-2023 | Stiolto Respimat, Ofev |
| Regeneron Healthcare Solutions, INC. | $16,643.88 | 2019-2021 | |
| Mylan Specialty L.P. | $13,292.60 | 2019-2022 | |
| Modernatx, INC. | $7,621.08 | 2023 | Moderna Covid-19 Vaccine |
| Sunovion Pharmaceuticals INC. | $4,978.73 | 2019 | |
| Pfizer INC. | $4,529.22 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $4,224.49 | 2019 | |
| Merck Sharp & Dohme LLC | $3,830.30 | 2019 | |
| Astrazeneca Uk Limited | $3,312.50 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $2,457.18 | 2019-2024 | |
| Intuitive Surgical, INC. | $504.19 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $291.14 | 2019 | |
| Genentech USA, INC. | $262.37 | 2019-2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $199.45 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $29.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Rizzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.